United Kingdom news - the latest biotech news from Labiotech.eu

Home United Kingdom Page 40

Latest Posts

T cell therapy adaptimmune 1

News and Trends 9 Jan 2018

Adaptimmune Gets the Green Light for its New T-cell Cancer Therapy

Following successful pilot studies, Adaptimmune will increase the dose of its T-cell therapy 10-fold to see if it remains safe, while also assessing its cancer-fighting capacity. Adaptimmune is a leader in the development of T-cell therapies for the treatment of cancer. It has been testing another one of its SPEAR T-cells in two pilot studies to determine […]

January 9, 2018 - 3 minutesmins - By Alex Dale

topivert ulcerative colitis trial

News and Trends 8 Jan 2018

Biotech in London Paves the Way for a New Therapy for Ulcerative Colitis

TopiVert has successfully completed a Phase I trial in ulcerative colitis with a new class of drug that could help reduce adverse side effects. The results of a Phase I trial run by London-based biotech TopiVert have shown potential for a new type of therapy for ulcerative colitis. The study revealed that the drug, called […]

January 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

liquid biopsy prostate cancer angle 1

News and Trends 8 Jan 2018

This British Liquid Biopsy Could Save Us $5000 per Prostate Cancer Patient

ANGLE’s liquid biopsy technology measures the expression of an important prostate cancer biomarker, helping to identify the best treatment for different groups of patients. ANGLE is a world leader in the development of liquid biopsies – a technique for the early detection of cancer, which doesn’t require invasive tissue samples. The biotech published results in […]

January 8, 2018 - 3 minutesmins - By Alex Dale

antibiotic resistance skin patch 1

News and Trends 8 Jan 2018

This Skin Patch Could Slow the Rate of Antibiotic Resistance

Researchers have developed a skin patch that delivers drugs directly into the blood, avoiding the gut which is a breeding ground for antibiotic resistance. Researchers at Queen’s University Belfast are developing a skin patch to deliver drugs through the skin and directly into the bloodstream via thousands of ‘microneedles’. The technology is being tested as a […]

January 8, 2018 - 3 minutesmins - By Alex Dale

best biotech articles 2017

Best in Biotech 26 Dec 2017

Interviews, Reviews and Tops: Our Best Biotech Articles from 2017

We love hearing from our readers, and we listen to what they like! Here are the long reads from our best biotech articles of 2017. We gave you a list of books to read this holiday season, but do you need something lighter for the post-Christmas daze? We’ve collected our most popular long articles of […]

December 26, 2017 - 6 minutesmins - By Evelyn Warner

summit therapeutics new antibiotic

More News! 21 Dec 2017

Oxford Biotech Makes a Latin American Deal for Its Antibiotic

In a deal worth up to €23.6M, Summit Therapeutics licensed the commercialization of its new antibiotic ridinilazole to Eurofarma. Oxford-based Summit Therapeutics is working on new antibiotics to fight antimicrobial resistance. Its candidate ridinilazole has attracted the attention of a Brazilian pharma, Eurofarma, and the pair has made a deal for $2.5M (€2.1M) upfront and […]

December 21, 2017 - 1 minutemin - By Evelyn Warner

ADVERTISEMENT

uk biotech life science strategy

More News! 21 Dec 2017

Britain’s Life Science Strategy: What UK Biotech Can Do From the Bottom Up

Britain has been making a concerted effort to grow its biotech sector, especially after Brexit. What’s the plan and what can UK biotech do? The last time I walked the the echoey corridors of the Palace of Westminster (UK parliament), I was a wee twelve-year old, on a mission to push forward legislation to prevent […]

December 21, 2017 - 6 minutesmins - By External Contributor

gene therapy orchard therapeutics

News and Trends 20 Dec 2017

British Gene Therapy Gets a Huge £85M Boost in Series B

Orchard Therapeutics has raised a big round of financing to gene therapy options for many rare diseases for which there are no treatments. London-based Orchard Therapeutics has managed to raise £85M (€96M) in Series B, an amount that will certainly give an important boost to its pipeline of gene therapy treatments for rare diseases. The […]

December 20, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

granulomatous disease orchard therapeutics

News and Trends 18 Dec 2017

British Biotech Takes Over Development of Gene Therapy for Rare Immune Disease

Orchard Therapeutics has licensed a gene therapy for the rare genetic disorder X-linked chronic granulomatous disease (X-CGD) from the non-profit Généthon. London-based Orchard Therapeutics is adding a new program to its pipeline of gene therapies. The company has obtained an exclusive license to a lentiviral vector to treat X-linked chronic granulomatous disease and the clinical trial data […]

December 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

gw pharma epilepsy blockbuster 2018 1

News and Trends 15 Dec 2017

Signed, Sealed. Will GW Pharma’s Epilepsy Treatment Be a 2018 Blockbuster?

GW Pharma might be about to join the likes of Genmab in the biotech blockbuster club, with its epilepsy drug predicted to achieve sales of close to $1B in 2018. GW Pharma develops therapies for a range of diseases, including autism, epilepsy and brain cancer using its cannabinoid product platform. In a rundown of the top 10 […]

December 15, 2017 - 2 minutesmins - By Alex Dale

izana bioscience

More News! 14 Dec 2017

New Biotech in Oxford Takes on Arthritis of the Spine

Izana Bioscience has been launched today to develop an antibody to treat ankylosing spondylitis, a form of arthritis that affects the spine. Oxford’s newest biotech, Izana Bioscience, has an exclusive license from Takeda to develop the antibody drug Namilumab (IZN-101) and a £1.35M grant from Innovate UK to fund a Phase II study. The company plans to […]

December 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

immunocore imcgp100 pim designation

News and Trends 12 Dec 2017

Immunotherapy for Uveal Melanoma is on Track for Early Access in the UK

The UK grants Immunocore access to a fast-track scheme that will make its immunotherapy IMCgp100 available to patients with uveal melanoma before approval. The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has deemed Immunocore’s technology worth being used by patients before it’s approved. The regulatory agency has granted Promising Innovative Medicines (PIM) designation to IMCgp100 for […]

December 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT